Erratum: Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis (Clinical Pharmacology and Therapeutics (2011) 89 (735-740) DOI:10.1038/clpt.2011.35);Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 5, 2011, Pages 735-740

  Schmitt, C ^a   Kuhn, B ^a   Zhang, X ^b   Kivitz, A J ^c   Grange, S ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c Altoona Center for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOCHROME P450; CYTOCHROME P450 3A4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TOCILIZUMAB; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG INFUSION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFESTATION; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

EID: 79955465387     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.138     Document Type: Erratum

References (35)

1. Clark E.S. & Jones B.C. Human cytochromes P450 and their role in metabolismbased drug-drug interaction. In Drug-Drug Interactions: Drugs and the Pharmaceutical Sciences (ed. Rodrigues, A.D.) 55-88 (Marcel Dekker, New york, 2002).
2. Markey S.P. Pathways of drug metabolism. In Principles of Clinical Pharmacology (ed. atkinson a.J.) 123-136 (academic Press, San Diego, Ca, 2001).
3. Aitken, A.E., Richardson, T.A. & Morgan, E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46, 123-149 (2006). (Pubitemid 43271186)
4. Kulmatycki, K.M. & Jamali, F. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J. Pharm. Pharm. Sci. 8, 602-625 (2005).
5. Madhok, R., Crilly, A., Watson, J. & Capell, H.A. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. 52, 232-234 (1993). (Pubitemid 23094315)
6. Sack, U., Kinne, R.W., Marx, T., Heppt, P., Bender, S. & Emmrich, F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol. Int. 13, 45-51 (1993). (Pubitemid 23247813)
7. Robak, T., Gladalska, A., Stepien, H. & Robak, E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 7, 347-353 (1998). (Pubitemid 28552768)
8. Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N. & Kakehi, T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, Tocilizumab, In patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959-3964 (2008).
9. Hirano, T. The biology of interleukin-6. Chem. Immunol. 51, 153-180 (1992).
10. Keller, E.T., Wanagat, J. & Ershler, W.B. Molecular and cellular biology of interleukin-6 and its receptor. Front. Biosci. 1, D340-d357 (1996).
11. Aitken, A.E. & Morgan, E.T. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3a4 mRNa levels in human hepatocytes. Drug Metab. Dispos. 35, 1687-1693 (2007). (Pubitemid 47296065)
12. Jover, R., Bort, R., Gómez-Lechón, M.J. & Castell, J.V. Down-regulation of human CyP3a4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 16, 1799-1801 (2002).
13. Zhang X., Schmitt C., Grange S., Terao K., Miya K. & Kivitz a. Disease-drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo. Clin. Pharmacol. Ther. 85, S59 (2009). abstract.
14. US Department of Health and Human Services. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data analysis, And Recommendations for Dosing and Labeling (1999).
15. Sato, K. et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53, 851-856 (1993). (Pubitemid 23077873)
16. Mihara, M. et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, But not by the receptors of other members of IL-6 cytokine family. Int. Immunopharmacol. 5, 1731-1740 (2005). (Pubitemid 41116745)
17. Nishimoto, N. et al. Toxicity, Pharmacokinetics, And dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRa in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 30, 1426-1435 (2003). (Pubitemid 36835435)
18. Nishimoto, N. et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106, 2627-2632 (2005). (Pubitemid 41510733)
19. Ito, H. et al. a pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996; Discussion 947 (2004). (Pubitemid 38451170)
20. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
21. Smolen, J.S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, Placebocontrolled, Randomised trial. Lancet 371, 987-997 (2008). (Pubitemid 351392039)
22. Genovese, M.C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968-2980 (2008).
23. Maini, R.N. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, Tocilizumab, In European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817-2829 (2006). (Pubitemid 44497760)
24. Jones, G. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the aMBITION study. Ann. Rheum. Dis. 69, 88-96 (2010).
25. Okamoto, H. et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J. Rheumatol. 34, 964-968 (2007). (Pubitemid 46774839)
26. Merck & Co., Inc. Zocor (simvastatin) tablet. Physicians Desk Reference Network Library Web Site .
27. Kyrklund, C., Backman, J.T., Kivistö, K.T., Neuvonen, M., Laitila, J. & Neuvonen, P.J. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 68, 592-597 (2000). (Pubitemid 32059984)
28. Kantola, T., Kivistö, K.T. & Neuvonen, P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 64, 177-182 (1998). (Pubitemid 28423853)
29. Najib, N.M. et al. Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharm. Drug Dispos. 24, 183-189 (2003). (Pubitemid 36939689)
30. Lilja, J.J., Neuvonen, M. & Neuvonen, P.J. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br. J. Clin. Pharmacol. 58, 56-60 (2004). (Pubitemid 38901467)
31. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.J. Duration of effect of grapefruit juice on the pharmacokinetics of the CyP3a4 substrate simvastatin. Clin. Pharmacol. Ther. 68, 384-390 (2000).
32. Yu, R.Z. et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), A 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNa, With simvastatin and ezetimibe. Clin. Pharmacokinet. 48, 39-50 (2009).
33. Prueksaritanont, T., Ma, B. & Yu, N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CyP3a, And not CyP2D6. Br. J. Clin. Pharmacol. 56, 120-124 (2003). (Pubitemid 36886497)
34. Frey, N., Grange, S. & Woodworth, T. Population analysis of tocilizumab in patients with rheumatoid arthritis. J. Clin. Pharmacol. 50, 754-766 (2010).
35. Gibaldi M. & Perrier D. Pharmacokinetics 2nd edn. (Marcel Dekker, New york, 1982).